Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis

Bibliography

• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder [Internet]. American Psychiatric Association, Washington, DC; 2010. Available from: http://psychiatryonline.com [Last accessed 8 May 2015]
   Google Scholar
• National Institute for Health and Clinical Excellence. Depression: The treatment and management of depression in adults (G90). National Institute for Health and Care Excellence; 2009. Available from: https://www.nice.org.uk/guidance/cg91/resources/guidance-depression-in-adults-with-a-chronic-physical-health-problem-pdf [Last accessed 1 September 2015]
   Google Scholar
• Härter M, Klesse C, Bermejo I, et al. Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. Dtsch Ärztebl Int 2010;107(40):700-8
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Eisfeld BS, Meyer JH, Bagby RM. Antidepressants in clinical practice: limitations of assessment methods and drug response. Hum Psychopharmacol 2001;16(1):105-14
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63(4):424-34
   PubMed Web of Science ®Google Scholar
• Bowden CL, Schatzberg AF, Rosenbaum A, et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 1993;13(5):305-11
   PubMed Web of Science ®Google Scholar
• Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993;13(6 Suppl 2):18S-22S
   PubMed Web of Science ®Google Scholar
• Ansseau M, Papart P, Troisfontaines B, et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology (Berl) 1994;114(1):131-7
   PubMed Web of Science ®Google Scholar
• Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995;56(6):229-37
   PubMed Web of Science ®Google Scholar
• Valenstein M, McCarthy JF, Austin KL, et al. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006;163(7):1219-25
   PubMed Web of Science ®Google Scholar
• Köhler S, Unger T, Hoffmann S, et al. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study. Pharmacopsychiatry 2013;46(2):69-76
   PubMed Web of Science ®Google Scholar
• Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009;19(7):457-65
   PubMed Web of Science ®Google Scholar
• Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010;167(3):281-8
   PubMed Web of Science ®Google Scholar
• Maes M, Libbrecht I, van Hunsel F, et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 1999;19(2):177-82
   PubMed Web of Science ®Google Scholar
• Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002;22(4):379-87
   PubMed Web of Science ®Google Scholar
• Dodd S, Horgan D, Malhi GS, Berk M. To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 2005;89(1-3):1-11
   PubMed Web of Science ®Google Scholar
• Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull 2009;42(3):57-90
   PubMed Web of Science ®Google Scholar
• Chang C-M, Sato S, Han C. Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression. CNS Drugs 2013;27(Suppl 1):S21-7
   PubMed Web of Science ®Google Scholar
• De la Gándara J, Agüera L, Rojo JE, et al. Use of antidepressant combinations: which, when and why? Results of a Spanish survey. Acta Psychiatr Scand 2005;112:32-5
   Web of Science ®Google Scholar
• Zimmerman M, Posternak M, Friedman M, et al. Which Factors Influence Psychiatrists’ Selection of Antidepressants? Am J Psychiatry 2004;161(7):1285-9
   PubMed Web of Science ®Google Scholar
• Rocha FL, Fuzikawa C, Riera R, Hara C. Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis. J Clin Psychopharmacol 2012;32(2):278-81
   PubMed Web of Science ®Google Scholar
• Lopes Rocha F, Fuzikawa C, Riera R, et al. Antidepressant combination for major depression in incomplete responders--a systematic review. J Affect Disord 2013;144(1-2):1-6
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011;71(1):43-64
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88
   PubMedGoogle Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. A Nonparametric “Trim and Fill” Method of Accounting for Publication Bias in Meta-Analysis. J Am Stat Assoc 2000;95(449):89-98
   Web of Science ®Google Scholar
• Akkaya C, Kirli S, Eker SS, et al. Comparison of the efficacy and safety of sertraline, reboxetine, and venlafaxine in patients with major depressive disorder: A pooled analysis of four randomized, open-label trials. Klin Psikofarmakol Bül Bull Clin Psychopharmacol 2010;20(4):274-87
   Web of Science ®Google Scholar
• Ball S, Dellva MA, D’Souza DN, et al. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. J Affect Disord 2014;167:215-23
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011;168(7):689-701
   PubMed Web of Science ®Google Scholar
• Dam J, Ryde L, Svejsø J, et al. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 1998;31(2):48-54
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151(9):1372-4
   PubMed Web of Science ®Google Scholar
• Ferreri M, Lavergne F, Berlin I, et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 2001;103(1):66-72
   PubMed Web of Science ®Google Scholar
• Fornaro M, Martino M, Mattei C, et al. Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2014;24(8):1269-78
   PubMed Web of Science ®Google Scholar
• Gulrez G, Badyal DK, Deswal RS, Sharma A. Bupropion as an augmenting agent in patients of depression with partial response. Basic Clin Pharmacol Toxicol 2012;110(3):227-30
   PubMed Web of Science ®Google Scholar
• Lauritzen L, Clemmesen L, Klysner R, et al. Combined treatment with imipramine and mianserin: A controlled pilot study. Pharmacopsychiatry 1992;25(4):182-6
   PubMed Web of Science ®Google Scholar
• Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 2002;161(2):143-51
   PubMed Web of Science ®Google Scholar
• Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996;41(3):201-10
   PubMed Web of Science ®Google Scholar
• Matreja PS, Badyal DK, Deswal RS, Sharma A. Efficacy and safety of add on low-dose mirtazapine in depression. Indian J Pharmacol 2012;44(2):173-7
   PubMed Web of Science ®Google Scholar
• Murphy JE. A comparative trial of Anafranil, Pertofran and an Anafranil/Pertofran combination. J Int Med Res 1977;5(1 Suppl):16-23
   PubMed Web of Science ®Google Scholar
• Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004;55(3):296-300
   PubMed Web of Science ®Google Scholar
• O’Brien S, McKeon P, O’Regan M, et al. Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline. J Clin Psychopharmacol 1992;12(2):104-9
   PubMed Web of Science ®Google Scholar
• Raisi FR, Habibi N, Nasehi AA, Mohammadi MR. Combination of Citalopram and Nortriptyline in Treatment of Moderate to Severe Major Depression: A Double-blind, Placebo-controlled Trial. Iran J Psychiatry 2006;1(1):35-8
   Google Scholar
• Stewart JW, McGrath PJ, Blondeau C, et al. Combination antidepressant therapy for major depressive disorder: speed and probability of remission. J Psychiatr Res 2014;52:7-14
   PubMed Web of Science ®Google Scholar
• Vezmar S, Miljkovic B, Vucicevic K, et al. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. J Pharmacol Sci 2009;110(1):98-104
   PubMed Web of Science ®Google Scholar
• Young JP, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J 1979;2(6201):1315-17
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002;51(2):183-8
   PubMed Web of Science ®Google Scholar
• Galling B, Garcia MA, Osuchukwu U, et al. Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf 2015;1-19
   PubMed Web of Science ®Google Scholar
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352(11):1112-20
   PubMed Web of Science ®Google Scholar
• Decoutere L, De Winter S, Vander Weyden L, et al. A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge. Int J Clin Pharm 2012;34(5):686-8
   Google Scholar
• Talarico G, Tosto G, Pietracupa S, et al. Serotonin toxicity: a short review of the literature and two case reports involving citalopram. Neurol Sci 2011;32(3):507-9
   PubMed Web of Science ®Google Scholar
• Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology 2010;86(4):203-15
   PubMed Web of Science ®Google Scholar
• Paslakis G, Gilles M, Deuschle M. Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series. J Clin Psychopharmacol 2010;30(4):473-4
   PubMed Web of Science ®Google Scholar
• Hori H, Yoshimura R, Ueda N, et al. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. World J Biol Psychiatry 2009;10(4 Pt 2):620-2
   PubMed Web of Science ®Google Scholar
• Vlase L, Leucuta A, Farcau D, Nanulescu M. Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharm Drug Dispos 2006;27(6):285-9
   PubMed Web of Science ®Google Scholar
• Sennef C, Timmer CJ, Sitsen JMA. Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol 2003;18(2):91-101
   PubMed Web of Science ®Google Scholar
• Purgato M, Papola D, Gastaldon C, et al. Paroxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2014;4:CD006531
   PubMedGoogle Scholar
• Magni LR, Purgato M, Gastaldon C, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2013;7:CD004185
   PubMedGoogle Scholar
• Cipriani A, Koesters M, Furukawa TA, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012;10:CD006533
   PubMedGoogle Scholar
• Cipriani A, Purgato M, Furukawa TA, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012;7:CD006534
   PubMed Web of Science ®Google Scholar
• Cipriani A, La Ferla T, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2010(4):CD006117
   Google Scholar
• Omori IM, Watanabe N, Nakagawa A, et al. Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2010(3):CD006114
   Google Scholar
• Watanabe N, Omori IM, Nakagawa A, et al. MANGA (Meta-Analysis of New Generation Antidepressants) Study Group. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010;24(1):35-53
   PubMed Web of Science ®Google Scholar
• Nakagawa A, Watanabe N, Omori IM, et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009(3):CD006529
   Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet Lond Engl 2009;373(9665):746-58
   PubMed Web of Science ®Google Scholar
• Kovacs D, Gonda X, Petschner P, et al. Antidepressant treatment response is modulated by genetic and environmental factors and their interactions. Ann Gen Psychiatry 2014;13:17
   PubMed Web of Science ®Google Scholar
• Fabbri C, Porcelli S, Serretti A. From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can J Psychiatry Rev Can Psychiatr 2014;59(2):62-75
   PubMed Web of Science ®Google Scholar